Thomas Dayspring: Antihypertensive Class and Dementia Risk
Thomas Dayspring, Lipidologist at Early Medical, shared on LinkedIn:
”Thanks to Kellyann Niotis M.D. for alerting me about the largest multinational cohort study conducted to date investigating different classes of antihypertensive drugs and the risk of incident dementia. The conclusion: physicians and patients should consider the reduced risk of all-cause dementia and Vascular Dementia with ARB compared with ACE-I in their risk–benefit assessment.”
Title: Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study
Authors: Edmund C L Cheung, Matthew Adesuyan, Máté Szilcz, Lisa M Kalisch Ellett, Sonia Shah, Yogini H Jani, Sara Hägg, Nicole Pratt, Kui Kai Lau, Hao Luo, Eric Yuk Fai Wan, Esther Wai Yin Chan, Ian C K Wong, Jacqueline K Yuen, Kai-Hang Yiu, Robert Howard, Ruth Brauer, Celine S L Chui
Read the full article here.
Stay updated with Hemostasis Today.
-
Jan 10, 2026, 08:56Shivanand Kumatagi Reflects on His Visit to Rela Hospital
-
Jan 10, 2026, 08:48Mitchell Elkind: Why Is The American Heart Association Holding a Brain Health Symposium?
-
Jan 10, 2026, 08:41Fiona Robinson Invites You to NBDF Webinar on Research Grants
-
Jan 10, 2026, 08:30Melissa Korn Takes Front Page Award for Her WSJ Piece on Experiencing a Pulmonary Embolism
-
Jan 10, 2026, 08:20Aymar Akilimali on Malaria in the Democratic Republic of Congo
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management